370 likes | 669 Views
Combined T4/T3 Therapy Summary of Studies. Bunevicius. N Engl J Med. 1999 Feb 11;340(6):424-9. Bunevicius. Int J Neuropsychopharmacol. 2000 Jun;3(2):167-174. Walsh et al. J Clin Endocrinol Metab. 2003 Oct;88(10):4543-50. Sawka et al. J Clin Endocrinol Metab. 2003 Oct;88(10):4551-5. Clyde. JAMA. 200
E N D
1. Thyroid Dysfunction:Pharmaceutical Considerations
2. Combined T4/T3 TherapySummary of Studies
3. T3 and T4 / T3 Therapy T3 has a very short half-life
Liothyronine
Synthetic
T3 is more biologically active that LT4
No indication for the use of T3 alone
Thyroid extract
Porcine-derived
T4 and T3
4. Brand
Chemistry
Manufacturing
Controls
Labeling
Testing
Preclinical/Clinical
Bioavailability Generic
Chemistry
Manufacturing
Controls
Labeling
Testing
Bioequivalence FDA Considerations for Approval: Brand and Generic The FDA looks at a number of processes and characteristics before approving either a generic or branded product. This list hits some of the key points. The brand drug’s preclinical and bioavailability studies are used to determine the generic’s BE.The FDA looks at a number of processes and characteristics before approving either a generic or branded product. This list hits some of the key points. The brand drug’s preclinical and bioavailability studies are used to determine the generic’s BE.
5. Definition of a Generic Drug A drug product that is the same as brand drug in:
Active ingredient
Strength
Dosage form
Route of administration
Quality
Therapeutic effect
6. Therapeutic Equivalents: Assumptions Pharmaceutical Equivalent + Bioequivalence = Therapeutic Equivalence
When administered under conditions specified in the labeling, expected to have the same:
Clinical effect
Safety profile
7. Bioequivalence
8. Area Under the Curve (AUC)
Measure of extent of absorption of drug into blood plasma
9. Pharmacokinetic Profile of a Reference Drug
10. Comparison of PK Profiles to Determine Bioequivalence
11. FDA Requirements for Bioequivalence FDA Requirements for Bioequivalence.
The rate and extent of absorption between a drug being tested and the reference drug is compared statistically using characteristics of concentration-time curves, such as AUC and Cmax.
For a drug to be approved as bioequivalent to the reference drug, its AUC and Cmax values must fall within a 90% confidence interval (CI), or between 80% and 125%, of the reference drug values.
In the example shown on this slide, Product A is bioequivalent to the reference drug. Its AUC value falls within 80% to 125% of the reference drug. Product B is not bioequivalent to the reference drug. Its AUC value falls outside of 80% to 125% of the reference drug.1
Reference
1. Approved Drug Products With Therapeutic Equivalence Evaluations. 23rd ed. 2003. FDA/CDER Web site. Available at: http://www.fda.gov/cder/ob/docs/preface/ecpreface.htm#Therapeutic Equivalence-Related Terms. Accessed September 29, 2003.
FDA Requirements for Bioequivalence.
The rate and extent of absorption between a drug being tested and the reference drug is compared statistically using characteristics of concentration-time curves, such as AUC and Cmax.
For a drug to be approved as bioequivalent to the reference drug, its AUC and Cmax values must fall within a 90% confidence interval (CI), or between 80% and 125%, of the reference drug values.
In the example shown on this slide, Product A is bioequivalent to the reference drug. Its AUC value falls within 80% to 125% of the reference drug. Product B is not bioequivalent to the reference drug. Its AUC value falls outside of 80% to 125% of the reference drug.1
Reference
1. Approved Drug Products With Therapeutic Equivalence Evaluations. 23rd ed. 2003. FDA/CDER Web site. Available at: http://www.fda.gov/cder/ob/docs/preface/ecpreface.htm#Therapeutic Equivalence-Related Terms. Accessed September 29, 2003.
12. FDA Coding Systemfor Therapeutic Equivalence Products receive “AB” ratings to signify bioequivalence or “BX” ratings to signify inequivalence.
If a product receives an AB rating, pharmacists may change to another AB-rated drug
13. Does a –20% to +25% difference in absorption have an effect on therapeutic outcomes?
15. What’s Unique About LT4? Thyroxine is an endogenous hormone and accounts for 70% of the AUC
In dosage form proportionality studies, the average contribution of endogenous thyroxine to AUC was 69% (range 52%-88%).
Data on file, Abbott Laboratories, Study M01-324.
In dosage form proportionality studies, the average contribution of endogenous thyroxine to AUC was 69% (range 52%-88%).
Data on file, Abbott Laboratories, Study M01-324.
18. Equivalence of Thyroxine Formulations
19. The Blakesley Study
20. Current BE standards cannot detect the difference between LT4 doses that differ by as much as:
21. Study Design N=36
LT4 doses administered
Regimen A: 600 mg (12 x 50 mg Synthroid)
Regimen B: 450 mg (9 x 50 mg Synthroid)
Regimen C: 400 mg (8 x 50 mg Synthroid)
The same Synthroid lot was used for all regimens
Followed FDA criteria for determining BE
23. Equivalence of Thyroxine Formulations
24. Equivalence of Thyroxine Formulations Sandoz Study Results
25. Implications of Sandoz Study Results Despite the absorption difference of ~12.5% between Synthroid and the generic, they are considered bioequivalent
26. LT4 Dosage Strengths in 1982
30. What Happens at the Pharmacy?
31. 3 Generic, 3 Reference, Several Brand Names Substitution Approved Drug Products With Therapeutic Equivalence Evaluations. 24th edition Cumulative Supplement 7. Center for Drug Evaluation and Research, FDA July 2004 www.fda.gov/cder/orange/supplement/cspreface.htm.
Approved Drug Products With Therapeutic Equivalence Evaluations. 24th edition Cumulative Supplement 7. Center for Drug Evaluation and Research, FDA July 2004 www.fda.gov/cder/orange/supplement/cspreface.htm.
32. Approved LT4 Products
33. Practical Advice Pick one LT4 brand for your patient, and do not allow generic substitution by protecting the prescription.
Confirm the LT4 brand the patient is taking at each visit.
Obtain serum TSH 8-12 weeks after LT4 dose or brand changes.
Consider brand substitution among the list of explanations for deviation of the TSH from the therapeutic goal range.
34. Professional Associations Guidance to Physicians and PatientsJune 24, 2004
35. Given the multiple sources of variation in the effects of a dose of the drug, there is no good reason to introduce another one by substituting a generic that could be switched without the prescriber’s knowledge from one refill to the next.
36. Internet References
American Association of Clinical Endocrinologists www.aace.com
American Thyroid Association www.thyroid.org
Thyroid Manager www.thyroidmanager.org
Thyroid Today www.thyroidtoday.com
National Cancer Institute www.cancer.gov (search “thyroid”)
www.thyroidpharmacovigilance.net/